Election Committee of XVIVO Perfusion AB (publ)

The following people have been appointed as members of XVIVO Perfusion’s
Election Committee for the 2017 Annual General Meeting:

Gösta Johannesson, representing Bure Equity AB
Martin Lewin, representing Eccenovo AB,
Thomas Olausson

The appointments have been made in accordance with the instructions regarding
principles for the appointment of the company Election Committee which were
determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on May 3,
2016.

The Annual General Meeting of XVIVO Perfusion AB (publ) will be held on April
26, 2017 in Gothenburg. Shareholders who wish to have an item considered at the
Annual General Meeting can submit a written request to the Board to this effect.
Such a request for an item to be considered is to be sent to XVIVO Perfusion AB
(publ), Att: Chairman of the Board, Box 53015, 400 14 Gothenburg, and must have
been received by the Board no later than seven weeks before the Annual General
Meeting, or otherwise in such good time that the matter, where necessary, can be
included in the notice to attend the Annual General Meeting.

September 20, 2016
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com


For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com
Xvivo Perfusion AB (publ) submitted the following information through the agency
of above contact person. The information was submitted for publication on
September 20, 2016 at 2:30 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund,
Sweden and one office in Denver, the USA. The XVIVO share is listed on NASDAQ
First North premier and has the ticker symbol XVIVO. More information can be
found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye,
www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com